Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 6/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 6/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 6/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217705 | 0.96 | CASP1 (0.35) | SLC1A3SLC1A2SLC1A1CASP1ALDH1A1 | |
| SCHEMBL18539083 | 0.86 | ALDH1A1 (0.42) | SLC1A3SLC1A2SLC1A1ALDH1A1MAPT | |
| SCHEMBL18499282 | 0.82 | ALDH1A1 (0.39) | SLC1A3SLC1A2SLC1A1ALDH1A1MAPT | |
| SCHEMBL19184705 | 0.80 | ALDH1A1 (0.38) | SLC1A3SLC1A2SLC1A1ALDH1A1MAPT | |
| SCHEMBL4960125 | 0.79 | LMNA (0.45) | SLC1A3SLC1A2SLC1A1ALDH1A1MAPT | |
| SCHEMBL19679637 | 0.78 | TSHR (0.44) | ALDH1A1MAPTTSHR | |
| SCHEMBL19184702 | 0.77 | ALDH1A1 (0.34) | ALDH1A1MAPTTSHRCYP2D6CYP2C19 | |
| SCHEMBL21229515 | 0.75 | ALDH1A1 (0.46) | SLC1A3SLC1A2SLC1A1ALDH1A1TSHR | |
| SCHEMBL16217702 | 0.74 | TSHR (0.42) | CASP1ALDH1A1MAPTTSHRCYP2D6 | |
| SCHEMBL28293945 | 0.70 | ALDH1A1 (0.56) | CASP1ALDH1A1MAPTTSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969822-B2 | Multifunctional monomers, methods for making multifunctional monomers, polymerizable compositions and products formed therefrom | SIRRUS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969822-B2 | Multifunctional monomers, methods for making multifunctional monomers, polymerizable compositions and products formed therefrom | SIRRUS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170050914-A1 | MULTIFUNCTIONAL MONOMERS, METHODS FOR MAKING MULTIFUNCTIONAL MONOMERS, POLYMERIZABLE COMPOSITIONS AND PRODUCTS FORMED THEREFORM | NIPPON SHOKUBAI CO., LTD. (JP) | 2017-02-23 | — | — | US | disclosed |
| US-20170050914-A1 | MULTIFUNCTIONAL MONOMERS, METHODS FOR MAKING MULTIFUNCTIONAL MONOMERS, POLYMERIZABLE COMPOSITIONS AND PRODUCTS FORMED THEREFORM | NIPPON SHOKUBAI CO., LTD. (JP) | 2017-02-23 | — | — | US | disclosed |
| US-9512058-B2 | Multifunctional monomers, methods for making multifunctional monomers, polymerizable compostions and products formed thereform | SIRRUS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9512058-B2 | Multifunctional monomers, methods for making multifunctional monomers, polymerizable compostions and products formed thereform | SIRRUS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140329980-A1 | MULTIFUNCTIONAL MONOMERS, METHODS FOR MAKING MULTIFUNCTIONAL MONOMERS, POLYMERIZABLE COMPOSTIONS AND PRODUCTS FORMED THEREFORM | SIRRUS, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140329980-A1 | MULTIFUNCTIONAL MONOMERS, METHODS FOR MAKING MULTIFUNCTIONAL MONOMERS, POLYMERIZABLE COMPOSTIONS AND PRODUCTS FORMED THEREFORM | SIRRUS, INC. | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050914-A1 | MULTIFUNCTIONAL MONOMERS, METHODS FOR MAKING MULTIFUNCTIONAL MONOMERS, POLYMERIZABLE COMPOSITIONS AND PRODUCTS FORMED THEREFORM | MACF1, BHMT2, MTHFD2 | SLC1A3 4227/4885SLC1A2 4194/4885SLC1A1 4029/4885 |
| US-20140329980-A1 | MULTIFUNCTIONAL MONOMERS, METHODS FOR MAKING MULTIFUNCTIONAL MONOMERS, POLYMERIZABLE COMPOSTIONS AND PRODUCTS FORMED THEREFORM | BHMT2, MTHFD2, BHMT | SLC1A3 4162/4885SLC1A2 4141/4885SLC1A1 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.